Detection of New Diabetes Cases During Post-COVID-19-Pandemic Period in a Panchayath of South Kerala
Authors
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Introduction: COVID-19 and diabetes mellitus have a bidirectional relationship as patients with diabetes are more susceptible to COVID and patients end up with new-onset diabetes after COVID-19 (NODAC). This study aims to estimate the proportion and risk factors of newly detected diabetes, during post-COVID19 pandemic period. Methods: We did analysis of data generated as part of an intensified screening campaign for non-communicable diseases in a Panchayat area in South Kerala. We included data of 2402 participants, who did not have a diagnosis of diabetes before the COVID-19 pandemic. Binary logistic regression was used to find the factors associated with detection of diabetes in post COVID-19 period. Results: Among 2402 eligible participants screened, 143 (5.95%) new cases of diabetes were detected. Binary logistic regression identified elderly age (P=.001, OR=1.86 [95%CI;1.28-2.71]), smoking habit (P=.001, OR=3.98[1.74-9.09]) and history of COVID-19 infection (P<.001, OR=3.80[2.52-5.73]) as determinants for detection of diabetes. Conclusion: Detection of new cases of diabetes during post pandemic period has increased. COVID-19 infection emerged as a significant risk factor for development of diabetes in addition to the traditional factors like age, smoking and family history. Community level screening activities has to be intensified, for strengthening secondary prevention of diabetes mellitus.
##plugins.themes.bootstrap3.article.details##
Copyright (c) 2025 Shibu Sukumaran, Khalid Khader, Chintha Sujatha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons License All articles published in Annals of Medicine and Medical Sciences are licensed under a Creative Commons Attribution 4.0 International License.
[1] Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119.
[2] Toniolo A, Cassani G, Puggioni A, Rossi A, Colombo A, Onodera T, et al. The diabetes pandemic and associated infections: suggestions for clinical microbiology. Rev Med Microbiol. 2019 Jan;30(1):1-17.
[3] Houeiss P, Luce S, Boitard C. Environmental Triggering of Type 1 Diabetes Autoimmunity. Front Endocrinol. 2022 Jul 22;13:933965.
[4] Zhang T, Mei Q, Zhang Z, Walline JH, Liu Y, Zhu H, et al. Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis. BMC Med. 2022 Nov 15;20(1):444.
[5] Davis PB, Xu R. COVID-19 and Incident Diabetes-Recovery Is Not So Sweet After All. JAMA Netw Open. 2023 Apr 18;6(4):e238872.
[6] Banerjee M, Pal R, Dutta S. Risk of incident diabetes post-COVID-19: A systematic review and meta-analysis. Prim Care Diabetes. 2022 Aug;16(4):591-3.
[7] Wihandani DM, Purwanta MLA, Mulyani WRW, Putra IWAS, Supadmanaba IGP. New-onset diabetes in COVID-19: The molecular pathogenesis. BioMedicine. 2023 Feb 22;13(1):3-12.
[8] Rezel-Potts E, Douiri A, Sun X, Chowienczyk PJ, Shah AM, Gulliford MC. Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK. Jia W, editor. PLOS Med. 2022 Jul 19;19(7):e1004052.
[9] Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022 May;10(5):311-21.
[10] Montefusco L, Ben Nasr M, D’Addio F, Loretelli C, Rossi A, Pastore I, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021 May 25;3(6):774-85.
[11] Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID ‐19. Diabetes Obes Metab. 2020 Oct;22(10):1897-906.
[12] Knight JS, Caricchio R, Casanova JL, Combes AJ, Diamond B, Fox SE, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021 Dec 15;131(24):e154886.
[13] Wu CT, Lidsky PV, Xiao Y, Lee IT, Cheng R, Nakayama T, et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab. 2021 Aug;33(8):1565-1576.e5.
[14] Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19. Diabetologia. 2022 Jun;65(6):949-54.
[15] Harding JL, Oviedo SA, Ali MK, Ofotokun I, Gander JC, Patel SA, et al. The bidirectional association between diabetes and long-COVID-19 - A systematic review. Diabetes Res Clin Pract. 2023 Jan;195:110202.
[16] Kreutzenberg SVD. Long COVID-19 and diabetes mellitus: a short review. Metab Target Organ Damage. 2023;3(1):4.
[17] Shrestha DB, Budhathoki P, Raut S, Adhikari S, Ghimire P, Thapaliya S, et al. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J Virol. 2021 Sep 25;10(5):275-87.
[18] Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021 May 19;n1098.
[19] Groß R, Kleger A. COVID-19 and diabetes - where are we now? Nat Metab. 2022 Nov 11;4(12):1611-3.
[20] Pantea Stoian A, Bica IC, Salmen T, Al Mahmeed W, Al-Rasadi K, Al-Alawi K, et al. New-Onset Diabetes Mellitus in COVID-19: A Scoping Review. Diabetes Ther [Internet]. 2023 Sep 26 [cited 2023 Nov 26]; Available from: https://link.springer.com/10.1007/s13300-023-01465-7